Nicole R. Hadas is CLO & VP at Akebia Therapeutics, Inc. (AKBA). They have made 17 open-market trades across 1 company since 2014, most recently 2024-05-13.
CIK 0001602396
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $60K since 2014, against 16 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AKBA | 651,243 | $450K |
Shares reported on the most recent Form 4, priced at the 2024-05-14 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AKBA | SELL · 10b5-1 | 2024-05-13 | 2024-05-14 | $1.26 | $15K | -9.8% | -8.2% | +0.8% |
| AKBA | SELL | 2024-02-29 | 2024-03-01 | $1.58 | $9K | -20.3% | -7.9% | -39.0% |
| AKBA | SELL · 10b5-1 | 2024-02-27 | 2024-02-29 | $1.52 | $11K | -9.6% | +3.8% | -34.4% |
| AKBA | SELL | 2023-05-25 | 2023-05-25 | $1.22 | $154K | +5.8% | -24.8% | +6.6% |
| AKBA | SELL | 2023-03-01 | 2023-03-03 | $0.88 | $11K | -30.0% | -39.8% | +13.6% |
| AKBA | SELL | 2023-02-27 | 2023-03-01 | $0.81 | $5K | -12.2% | -34.8% | +11.5% |
| AKBA | SELL | 2022-02-28 | 2022-03-02 | $2.16 | $46K | -3.2% | -73.0% | -85.0% |
| AKBA | SELL | 2021-04-01 | 2021-04-01 | $3.40 | $4K | -7.3% | -5.4% | +12.8% |
| AKBA | SELL | 2021-03-01 | 2021-03-02 | $3.40 | $49K | +3.5% | -4.5% | -2.2% |
| AKBA | SELL | 2020-02-28 | 2020-03-02 | $8.70 | $123K | -33.2% | -26.6% | +22.9% |
| AKBA | SELL | 2017-10-02 | 2017-10-04 | $19.92 | $280K | -7.4% | -10.5% | -24.7% |
| AKBA | SELL | 2017-07-03 | 2017-07-06 | $14.26 | $22K | -6.0% | -9.9% | +32.7% |
| AKBA | SELL | 2017-04-03 | 2017-04-04 | $9.18 | $14K | +2.5% | +44.7% | +64.9% |
| AKBA | SELL | 2017-01-01 | 2017-01-03 | $10.49 | $19K | -6.3% | -9.0% | -15.5% |
| AKBA | SELL | 2016-10-01 | 2016-10-04 | $8.95 | $14K | -10.5% | -20.6% | +16.0% |
| AKBA | SELL | 2016-07-05 | 2016-07-06 | $7.47 | $12K | +5.2% | +9.7% | +11.6% |
| AKBA | SELL | 2016-04-04 | 2016-04-05 | $9.41 | $15K | +3.3% | -6.0% | -22.0% |
| AKBA | SELL | 2016-01-04 | 2016-01-06 | $12.28 | $22K | -8.9% | -12.9% | +12.6% |
| AKBA | SELL · 10b5-1 | 2015-10-02 | 2015-10-05 | $8.67 | $13K | -38.5% | -0.9% | -0.9% |
| AKBA | SELL · 10b5-1 | 2015-07-02 | 2015-07-06 | $9.54 | $14K | -38.5% | -0.9% | -0.9% |
| AKBA | SELL · 10b5-1 | 2015-04-02 | 2015-04-06 | $9.09 | $13K | -38.5% | -0.9% | -0.9% |
| AKBA | SELL · 10b5-1 | 2015-01-02 | 2015-01-05 | $11.46 | $20K | -38.5% | -0.9% | -0.9% |
| AKBA | BUY | 2014-03-25 | 2014-03-27 | $17.00 | $60K | -38.5% | -0.9% | -0.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.